Senseonics narrows FY25 revenue view to $35M from $34M-$38M, consensus $36.12M

The company said, “Senseonics (SENS) expects full-year 2025 global net revenue to be approximately $35 million as we continue to roll out Eversense 365 to U.S. patients. The full-year 2025 financial outlook assumes approximately doubling of our global patient base during 2025, and revenue will be heavily weighted to the fourth quarter due to the once-a-year Eversense 365 reorder dynamics following its Q4 2024 launch. The financial outlook takes into consideration current assumptions regarding: refined visibility of the timeline and specifications for the regulatory approval and the plans for commercial transition to Eversense 365 outside the United States, projected plans with respect to spending on the DTC marketing campaign to generate additional leads, executing on other sales and marketing initiatives, anticipated utilization and impact of the patient assistance programs for Eversense 365, and continued progress with the transition of reimbursement from Eversense E3 to Eversense 365. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 35% and 40% for the full year. Cash used in operations in 2025 is expected to be approximately $60 million.”